Results 21 to 30 of about 193,589 (341)
Switching to Tenecteplase for Stroke Thrombolysis
Stroke, 2021 Supplemental Digital Content is available in the text. Background and Purpose: Due to practical advantages, increasing trial safety data, recent Australian Guideline endorsement and local population needs we switched to tenecteplase for stroke ...
K. Mahawish +5 more
semanticscholar +1 more source
Advancement of science, 2021 Thrombotic cardio‐cerebrovascular diseases seriously threaten human health. Currently, conventional thrombolytic treatments are challenged by the low utilization, inferior thrombus penetration, and high off‐target bleeding risks of most thrombolytic ...
Zhiqiang Zhao +12 more
semanticscholar +1 more source
Медицинский вестник Юга России, 2015 Purpose: to evaluate the rate and severity of filtration renal dysfunction in patients with acute coronary syndrome after percutaneous coronary intervention (PCI) with X-ray contrast.Materials and Methods: serum creatinine levels were collected from 71 ...
N. T. Vatutin, M. I. Zinkovych
doaj +1 more source
British Medical Bulletin, 2000 The most widely studied thrombolytic drugs in stroke have been streptokinase (SK) and alteplase. The three large trials with streptokinase were terminated prematurely. The combined results reveal an early increased risk of cerebral haemorrhage and death, with no net benefit at final follow-up, even in subgroups. Some controversy persists, however.
openaire +2 more sources
Local Thrombolysis in High-Risk Pulmonary Embolism—13 Years Single-Center Experience
Clinical and Applied Thrombosis/Hemostasis, 2020 To evaluate the prognosis after local thrombolysis compared to systemic thrombolysis in high-risk pulmonary embolism. Observational study during 13 years which included 37 patients with high-risk pulmonary embolism treated with local thrombolysis and 36 ...
Liviu Macovei MD, PhD +7 more
doaj +1 more source
Tissue plasminogen activator dose and pulmonary artery pressure reduction in catheter directed thrombolysis of submassive pulmonary embolism. [PDF]
, 2019 PURPOSE:The purpose of this study is to assess the incremental effect of tissue plasminogen activator (t-PA) dose on pulmonary artery pressure (PAP) and bleeding during catheter directed thrombolysis (CDT) of submassive pulmonary embolism (PE). MATERIALS
Gaba, Ron C +3 more
core +2 more sources
Ultrasound and thrombolysis [PDF]
Vascular Medicine, 2001 Thrombolytic therapy and mechanical interventions are frequently used in the treatment of both arterial and venous thrombotic disease. Limitations to these approaches include failure to achieve reperfusion and complications including bleeding and vessel wall damage.
Charles W. Francis, Valentina Suchkova
openaire +3 more sources
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2017 BackgroundUnderstanding the relative risk of cardiovascular versus noncardiovascular death is important for designing clinical trials. These risks may differ depending on patient age, sex, and type of acute coronary syndrome (ACS).
Alexander C. Fanaroff +9 more
doaj +1 more source
Multidisciplinary Approach to Decrease In-Hospital Delay for Stroke Thrombolysis [PDF]
Journal of Stroke, 2017 Background and Purpose Decreasing the time delay for thrombolysis, including intravenous thrombolysis (IVT) with tissue plasminogen activator and intra-arterial thrombectomy (IAT), is critical for decreasing the morbidity and mortality of patients ...
Sang-Beom Jeon +20 more
doaj +1 more source
Stroke with unknown time of symptom onset: baseline clinical and magnetic resonance imaging data of the first thousand patients in WAKE-UP (efficacy and safety of mri-based thrombolysis in wake-up stroke: a randomized, doubleblind, placebo-controlled trial) [PDF]
, 2017 Background and Purpose—We describe clinical and magnetic resonance imaging (MRI) characteristics of stroke patients with unknown time of symptom onset potentially eligible for thrombolysis from a large prospective cohort.
Boutitie, Florent +18 more
core +2 more sources